Effectiveness of acupuncture for cancer-related fatigue: a systematic reviews and meta-analysis - Top-Institutions - MDSpire

Effectiveness of acupuncture for cancer-related fatigue: a systematic reviews and meta-analysis

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Oncology
    • Integrative Medicine

  • #2

    University of Michigan
    University of Michigan

    Ann Arbor, MI

    Key Differentiators

    • Oncology

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Oncology

  • #4

    University of California Irvine’s School of Pharmacy & Pharmaceutical Sciences
    University of California Irvine’s School of Pharmacy & Pharmaceutical Sciences

    Irvine, CA

    Key Differentiators

    • Oncology
    • Pharmaceutical Sciences

  • #5

    Multinational Association of Supportive Care in Cancer (MASCC)
    Multinational Association of Supportive Care in Cancer (MASCC)

    N/A, N/A

    Key Differentiators

    • Oncology
    • Supportive Care

Original Source(s)

Effectiveness of acupuncture for cancer-related fatigue: a systematic reviews and meta-analysis

  • by Hongxiao Zhang, Zhifeng Pan, Yuting Huang, Run Lin, Liying Wang, Tao Peng, Mingzhu Xu, Zining Guo, Shaoyang Cui

  • May 5, 2026

Related Content

This Week’s Biopharma News: EU Clears First Pertuzumab Biosimilar

Plus: NICE backs rozanolixizumab for uncontrolled gMG, Genexine reports SOX2 degrader data, and BeOne secures option on Huahui trispecific antibody

  • May 5, 2026

  • 5 min
COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings

Patients diagnosed with metastatic breast cancer and non–small cell lung cancer had longer survival compared to national benchmarks when treated in independent community oncology practices, according ...

Zoldonrasib in Patients With <em>KRAS</em> G12D–Mutant NSCLC Previously Treated With Chemoimmunotherapy

The investigational KRAS G12D inhibitor zoldonrasib had a favorable safety profile and induced antitumor activity in some patients with KRAS G12D–mutated non–small cell lung cancer (NSCLC) who were pr...